肺癌患者血清miRNA-22表达水平及临床意义探讨  

Expression level of serum miRNA-22 and its clinical significance in patients with lung cancer

作　　者：杨侠[1] 张秋红[1] 苏文媚 张明[1] 单虎[1] 张洁[1] 陈国安 郭春芳 李雅莉[1] Yang Xia;Zhang Qiuhong;Su Wenmei;Zhang Ming;Shan Hu;Zhang Jie;Chen Guoan;Guo Chunfang;Li Yali(Department of Res piratory and Critical Care Medicine, the Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710004, China;Department of Oncology, Affiliated Hospital ofGuangdong Medical University, Zhanjiang 524000, China;School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China;Department of ThoracicSurgery University of Michigan, Amn Arbor 48109, America)

机构地区：[1]西安交通大学第二附属医院呼吸与危重症医学科,710004 [2]广东医科大学附属医院肿瘤科,湛江524000 [3]南方科技大学医学院,深圳518000 [4]美国密西根大学胸外科,安娜堡48109

出　　处：《国际呼吸杂志》2019年第18期1373-1378,共6页International Journal of Respiration

基　　金：陕西省重点研发计划一般项目(2018SF-074).

摘　　要：目的探讨miRNA-22(miR-22)在肺癌患者血清中的表达水平及其在肺癌诊断中的应用价值.方法收集116例非小细胞肺癌(NSCLC)患者、10例小细胞肺癌(SCLC)患者和152例非肺癌对照组的血清,采用荧光定量聚合酶链反应检测m iR-22表达水平,受试者工作特征曲线分析评价其对肺癌的诊断价值.结果血清miR-22在NSCLC患者、SCLC患者和非肺癌对照组中的相对表达量分别为1.63±1.43、1.10±1.64和-0.02±1.31,NSCLC患者miR-22表达水平高于SCLC患者及非肺癌对照组(F=49.35,P<0.01),SCLC患者与非肺癌对照组比较差异无统计学意义(P>0.05).血清miR-22在NSCLCⅠ期、Ⅱ期和Ⅲ/Ⅳ期患者的相对表达量分别为1.65±1.36、1.49±1.60和1.0±1.42,与非肺癌对照组比较均明显升高(P值均<0.05),但各期肺癌之间比较差异均无统计学意义(P值均>0.05).在NSCLC不同病理亚型(腺癌、鳞癌和大细胞癌)之间进行比较,m iR-22表达水平差异均无统计学意义(P值均>0.05).以非肺癌对照组作为阴性对照,NSCLC患者及其各病理亚型、各临床分期的曲线下面积在0.72~0.82之间.当分别取最佳临界值时,敏感度为70.59%~75.32%,特异度为54.61%~73.03%.结论血清m iR-22水平对肺癌早期诊断具有重要意义,作为非侵袭性的检测手段,m iR-22有望成为肺癌早期诊断的新指标.Objective To investigate the expression of miRNA-22 ( miR-22 ) in serum of patients with lung cancer and its value in the diagnosis of lung cancer .Methods Serum samples were collected from total 116 non-small cell lung cancer ( NSCLC) cases ,10 small cell lung cancer (SCLC) cases and 152 cancer-free controls .The expression of serum miR-22 was evaluated in all the samples by quantitative real time RT-PCR .Receiver operating characteristic curve ( ROC ) analysis was used to evaluate the impact of miR-22 on its diagnostic value for lung cancer .Results The relative expressions of serum miR-22 in NSCLC patients ,SCLC patients and cancer-free controls were 1 .63 ± 1 .43 ,1 .10 ± 1 .64 and -0 .02 ± 1 .31 ,respectively .The expression of miR-22 in NSCLC patients was higher than that in SCLC patients and cancer-free controls ( F =49 .35 , P <0 .01) .while no significant difference was observed between SCLC and cancer-free controls ( P >0 .05) .Moreover ,the expressions of miR-22 in patients with stage Ⅰ ,Ⅱ and Ⅲ / Ⅳ NSCLC were 1 .65 ± 1 .36 ,1 .49 ± 1 .60 and 1 .00 ± 1 .42 respectively and they were all higher than cancer-free controls ( all P < 0 .05 ) .No significant difference of miR-22 expression was found among Ⅰ-Ⅳstages of NSCLC(all P >0 .05) .There was no significant difference of miR-22 expression among different pathological subtypes of NSCLC :adenocarcinoma ,squamous cell carcinoma ,and large cell lung cancer ( all P > 0 .05 ) .ROC analyses were performed using cancer-free group as negative control and the area under curve values of serum miR-22 were ranged between 0 .72-0 .82 in either NSCLC group ,or its histological subtypes or different stages .When optimal cut-offs were selected the sensitivities and specificities were 70 .59%-75 .32% and 54 .61%-73 .03% respectively . Conclusions These data indicated serum miR-22 is of great significance for early diagnosis of lung cancer .As a non-invasive detection method ,microRNA-22 is expected to become a new indicator for early diagnosis of lung

关 键 词：癌 非小细胞肺 肿瘤标记 生物学 早期诊断 miR-22 

分 类 号：R734.2[医药卫生—肿瘤]